OncoFluvec (VTH-202) / Vacthera - LARVOL DELTA

Post-Transplant Cyclophosphamide GVHD Prophylaxis Has a Unique Vascular Toxicity Compared to Abatacept Containing Regimens. (TCT-ASTCT-CIBMTR 2026) - "Introduction: Post-transplant cyclophosphamide (PTCy) reduces acute graft versus host disease (GVHD) but alters vascular biomarkers, with an increase in angiopoietin -2 at day+28 post hematopoietic stem cell transplant (HSCT) in adult transplant recipients (Newell et al, Blood VTH 2024)... Patients were categorized into four GVHD prophylaxis cohorts 1) Cyclosporine (CSA) and mycophenolate mofetil (MMF), 2) CSA, MMF and abatacept, 3) post-transplant cyclophosphamide (PTCy) and 4) T cell depleted (TCD) graft... Vascular biomarkers of endothelial injury and clinical TA-TMA were higher in the PTCy group compared to the patients that received abatacept as part of their GVHD prophylaxis. The incidence of aGVHD was higher in the PTCy group. Further studies of the use of abatacept as part of GVHD prophylaxis regimens in children and specific vascular biomarkers should be studied further."

Post-transplantation • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation • Transplantation Associated Thrombotic Microangiopathy • FLT1 • ST2